Skip to main content
NCBI home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2008 Nov 15:1–18. doi: 10.1007/978-1-84800-925-7_20

Diseases of the Pulmonary Vascular System

Peter Oishi 1,✉, Jeffrey R Fineman 2
Editors: Derek S Wheeler1, Hector R Wong2, Thomas P Shanley3
PMCID: PMC7124039

The content is available as a PDF (548.7 KB).

Contributor Information

Derek S. Wheeler, Phone: +1513636-4259, Email: derek.wheeler@cchmc.org

Hector R. Wong, Phone: +1(513)636-4259, Email: wonghr@cchmc.org

Thomas P. Shanley, Phone: +1734764-5302, Email: tshanley@med.umich.edu

References

  • 1.McIntyre TM, Zimmerman GA, Satoh K, Prescott SM. Cultured endothelial cells synthesize both platelet-activating factor and prostacyclin in response to histamine, bradykinin, and adenosine triphosphate. J Clin Invest. 1985;76(1):271–280. doi: 10.1172/JCI111957. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332(6163):411–415. doi: 10.1038/332411a0. [DOI] [PubMed] [Google Scholar]
  • 3.Palmer RM, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature. 1988;333(6174):664–666. doi: 10.1038/333664a0. [DOI] [PubMed] [Google Scholar]
  • 4.Rubanyi GM, Romero JC, Vanhoutte PM. Flow-induced release of endothelium-derived relaxing factor. Am J Physiol. 1986;250(6 Pt 2):H1145–H1149. doi: 10.1152/ajpheart.1986.250.6.H1145. [DOI] [PubMed] [Google Scholar]
  • 5.Fiscus RR. Molecular mechanisms of endothelium-mediated vasodilation. Semin Thromb Haemost. 1988;14(Suppl):12–22. [PubMed] [Google Scholar]
  • 6.Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med. 1993;329(27):2002–2012. doi: 10.1056/NEJM199312303292706. [DOI] [PubMed] [Google Scholar]
  • 7.Fineman JR, Heymann MA, Soifer SJ. N omega-nitro-L-arginine attenuates endothelium-dependent pulmonary vasodilation in lambs. Am J Physiol. 1991;260(4 Pt 2):H1299–H1306. doi: 10.1152/ajpheart.1991.260.4.H1299. [DOI] [PubMed] [Google Scholar]
  • 8.Dinh-Xuan AT. Endothelial modulation of pulmonary vascular tone. Eur Respir J. 1992;5(6):757–762. [PubMed] [Google Scholar]
  • 9.Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest. 1989;83(5):1774–1777. doi: 10.1172/JCI114081. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Fineman JR, Chang R, Soifer SJ. EDRF inhibition augments pulmonary hypertension in intact newborn lambs. Am J Physiol. 1992;262(5 Pt 2):H1365–H1371. doi: 10.1152/ajpheart.1992.262.5.H1365. [DOI] [PubMed] [Google Scholar]
  • 11.Fineman JR, Crowley MR, Heymann MA, Soifer SJ. In vivo attenuation of endothelium-dependent pulmonary vasodilation by methylene blue. J Appl Physiol. 1991;71(2):735–741. doi: 10.1152/jappl.1991.71.2.735. [DOI] [PubMed] [Google Scholar]
  • 12.Braner DA, Fineman JR, Chang R, Soifer SJ. M8B 22948, a cGMP phosphodiesterase inhibitor, is a pulmonary vasodilator in lambs. Am J Physiol. 1993;264(1 Pt 2):H252–H258. doi: 10.1152/ajpheart.1993.264.1.H252. [DOI] [PubMed] [Google Scholar]
  • 13.Kourembanas S, McQuillan LP, Leung GK, Faller DV. Nitric oxide regulates the expression of vasoconstrictors and growth factors by vascular endothelium under both normoxia and hypoxia. J Clin Invest. 1993;92(1):99–104. doi: 10.1172/JCI116604. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Budhiraja R, Tuder RM, Hassoun PM. Endothelial dysfunction in pulmonary hypertension. Circulation. 2004;109(2):159–165. doi: 10.1161/01.CIR.0000102381.57477.50. [DOI] [PubMed] [Google Scholar]
  • 15.Matsuura A, Kawashima S, Yamochi W, Hirata K, Yamaguchi T, Emoto N, et al. Vascular endothelial growth factor increases endothelin- converting enzyme expression in vascular endothelial cells. Biochem Biophys Res Commun. 1997;235(3):713–716. doi: 10.1006/bbrc.1997.6885. [DOI] [PubMed] [Google Scholar]
  • 16.Cassin S, Kristova V, Davis T, Kadowitz P, Gause G. Tone-dependent responses to endothelin in the isolated perfused fetal sheep pulmonary circulation in situ. J Appl Physiol. 1991;70(3):1228–1234. doi: 10.1152/jappl.1991.70.3.1228. [DOI] [PubMed] [Google Scholar]
  • 17.Wong J, Vanderford PA, Fineman JR, Chang R, Soifer SJ. Endothelin-1 produces pulmonary vasodilation in the intact newborn lamb. Am J Physiol. 1993;265(4 Pt 2):H1318–H1325. doi: 10.1152/ajpheart.1993.265.4.H1318. [DOI] [PubMed] [Google Scholar]
  • 18.Wong J, Vanderford PA, Fineman JR, Soifer SJ. Developmental effects of endothelin-1 on the pulmonary circulation in sheep. Pediatr Res. 1994;36(3):394–401. doi: 10.1203/00006450-199409000-00021. [DOI] [PubMed] [Google Scholar]
  • 19.Bradley LM, Czaja JF, Goldstein RE. Circulatory effects of endothelin in newborn piglets. Am J Physiol. 1990;259(5 Pt 2):H1613–H1617. doi: 10.1152/ajpheart.1990.259.5.H1613. [DOI] [PubMed] [Google Scholar]
  • 20.Perreault T, De Marte J. Maturational changes in endothelium-derived relaxations in newborn piglet pulmonary circulation. Am J Physiol. 1993;264(2 Pt 2):H302–H309. doi: 10.1152/ajpheart.1993.264.2.H302. [DOI] [PubMed] [Google Scholar]
  • 21.Rudolph AM, Heymann MA. Circulatory changes during growth in the fetal lamb. Circ Res. 1970;26(3):289–299. doi: 10.1161/01.res.26.3.289. [DOI] [PubMed] [Google Scholar]
  • 22.Celermajer DS, Cullen S, Deanfield JE. Impairment of endothelium-dependent pulmonary artery relaxation in children with congenital heart disease and abnormal pulmonary hemodynamics. Circulation. 1993;87(2):440–446. doi: 10.1161/01.cir.87.2.440. [DOI] [PubMed] [Google Scholar]
  • 23.Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med. 1995;333(4):214–221. doi: 10.1056/NEJM199507273330403. [DOI] [PubMed] [Google Scholar]
  • 24.Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 1993;328(24):1732–1739. doi: 10.1056/NEJM199306173282402. [DOI] [PubMed] [Google Scholar]
  • 25.Reddy VM, Wong J, Liddicoat JR, Johengen M, Chang R, Fineman JR. Altered endothelium-dependent responses in lambs with pulmonary hypertension and increased pulmonary blood flow. Am J Physiol. 1996;271(2 Pt 2):H562–H570. doi: 10.1152/ajpheart.1996.271.2.H562. [DOI] [PubMed] [Google Scholar]
  • 26.Levin DL, Rudolph AM, Heymann MA, Phibbs RH. Morphological development of the pulmonary vascular bed in fetal lambs. Circulation. 1976;53(1):144–151. doi: 10.1161/01.cir.53.1.144. [DOI] [PubMed] [Google Scholar]
  • 27.Iwamoto HS, Teitel D, Rudolph AM. Effects of birth-related events on blood flow distribution. Pediatr Res. 1987;22(6):634–640. doi: 10.1203/00006450-198712000-00004. [DOI] [PubMed] [Google Scholar]
  • 28.Rudolph AM. Fetal and neonatal pulmonary circulation. Annu Rev Physiol. 1979;41:383–395. doi: 10.1146/annurev.ph.41.030179.002123. [DOI] [PubMed] [Google Scholar]
  • 29.Dawes GS, Mott JC, Widdicombe JG, Wyatt DG. Changes in the lungs of the new-born lamb. J Physiol. 1953;121(1):141–162. doi: 10.1113/jphysiol.1953.sp004936. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Heyman MA, Soifer S. Control of the fetal and neonatal pulmonary circulation. In: Weir EK, Reeves JT, editors. Pulmonary Vascular Physiology and Pathophysiology. New York: Dekker; 1989. [Google Scholar]
  • 31.Rudolph AM. Distribution and regulation of blood flow in the fetal and neonatal lamb. Circ Res. 1985;57(6):811–821. doi: 10.1161/01.res.57.6.811. [DOI] [PubMed] [Google Scholar]
  • 32.Fineman JR, Soifer SJ, Heymann MA. Regulation of pulmonary vascular tone in the perinatal period. Annu Rev Physiol. 1995;57:115–134. doi: 10.1146/annurev.ph.57.030195.000555. [DOI] [PubMed] [Google Scholar]
  • 33.Enhorning G, Adams FH, Norman A. Effect of lung expansion on the fetal lamb circulation. Acta Paediatr Scand. 1966;55(5):441–451. doi: 10.1111/j.1651-2227.1966.tb15234.x. [DOI] [PubMed] [Google Scholar]
  • 34.Leffler CW, Hessler JR, Green RS. The onset of breathing at birth stimulates pulmonary vascular prostacyclin synthesis. Pediatr Res. 1984;18(10):938–942. doi: 10.1203/00006450-198410000-00006. [DOI] [PubMed] [Google Scholar]
  • 35.Tiktinsky MH, Morin FC., 3rd Increasing oxygen tension dilates fetal pulmonary circulation via endothelium-derived relaxing factor. Am J Physiol. 1993;265(1 Pt 2):H376–H3780. doi: 10.1152/ajpheart.1993.265.1.H376. [DOI] [PubMed] [Google Scholar]
  • 36.Shaul PW, Farrar MA, Zellers TM. Oxygen modulates endothelium-derived relaxing factor production in fetal pulmonary arteries. Am J Physiol. 1992;262(2 Pt 2):H355–H364. doi: 10.1152/ajpheart.1992.262.2.H355. [DOI] [PubMed] [Google Scholar]
  • 37.Shaul PW, Farrar MA, Magness RR. Pulmonary endothelial nitric oxide production is developmentally regulated in the fetus and newborn. Am J Physiol. 1993;265(4 Pt 2):H1056–H1063. doi: 10.1152/ajpheart.1993.265.4.H1056. [DOI] [PubMed] [Google Scholar]
  • 38.Cornfield DN, Chatfield BA, McQueston JA, McMurtry IF, Abman SH. Effects of birth-related stimuli on L-arginine-dependent pulmonary vasodilation in ovine fetus. Am J Physiol. 1992;262(5 Pt 2):H1474–H1481. doi: 10.1152/ajpheart.1992.262.5.H1474. [DOI] [PubMed] [Google Scholar]
  • 39.Black SM, Johengen MJ, Ma ZD, Bristow J, Soifer SJ. Ventilation and oxygenation induce endothelial nitric oxide synthase gene expression in the lungs of fetal lambs. J Clin Invest. 1997;100(6):1448–1458. doi: 10.1172/JCI119665. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Fineman JR, Wong J, Morin FC, 3rd, Wild LM, Soifer SJ. Chronic nitric oxide inhibition in utero produces persistent pulmonary hypertension in newborn lambs. J Clin Invest. 1994;93(6):2675–2683. doi: 10.1172/JCI117281. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Beghetti M, Black SM, Fineman JR. Endothelin-1 in congenital heart disease. Pediatr Res. 2005;57(5 Pt 2):16R–20R. doi: 10.1203/01.PDR.0000160447.83332.13. [DOI] [PubMed] [Google Scholar]
  • 42.Black S, Fineman J, Johengen M, Bristow J, Soifer S. Increased pulmonary blood flow alters the molecular regulation of vascular reactivity in the lamb. Chest. 1998;114(1 Suppl):39S. doi: 10.1378/chest.114.1_supplement.39s. [DOI] [PubMed] [Google Scholar]
  • 43.Black SM, Bekker JM, Johengen MJ, Parry AJ, Soifer SJ, Fineman JR. Altered regulation of the ET-1 cascade in lambs with increased pulmonary blood flow and pulmonary hypertension. Pediatr Res. 2000;47(1):97–106. doi: 10.1203/00006450-200001000-00018. [DOI] [PubMed] [Google Scholar]
  • 44.Black SM, Bekker JM, McMullan DM, Parry AJ, Ovadia B, Reinhartz O, et al. Alterations in nitric oxide production in 8-week-old lambs with increased pulmonary blood flow. Pediatr Res. 2002;52(2):233–244. doi: 10.1203/00006450-200208000-00016. [DOI] [PubMed] [Google Scholar]
  • 45.Black SM, Fineman JR, Steinhorn RH, Bristow J, Soifer SJ. Increased endothelial NOS in lambs with increased pulmonary blood flow and pulmonary hypertension. Am J Physiol. 1998;275(5 Pt 2):H1643–H1651. doi: 10.1152/ajpheart.1998.275.5.H1643. [DOI] [PubMed] [Google Scholar]
  • 46.Black SM, Mata-Greenwood E, Dettman RW, Ovadia B, Fitzgerald RK, Reinhartz O, et al. Emergence of smooth muscle cell endothelin B–mediated vasoconstriction in lambs with experimental congenital heart disease and increased pulmonary blood flow. Circulation. 2003;108(13):1646–1654. doi: 10.1161/01.CIR.0000087596.01416.2F. [DOI] [PubMed] [Google Scholar]
  • 47.Black SM, Sanchez LS, Mata-Greenwood E, Bekker JM, Steinhorn RH, Fineman JR. sGC and PDE5 are elevated in lambs with increased pulmonary blood flow and pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2001;281(5):L1051–L1057. doi: 10.1152/ajplung.2001.281.5.L1051. [DOI] [PubMed] [Google Scholar]
  • 48.Fineman JR, Wong J, Mikhailov T, Vanderford PA, Jerome HE, Soifer SJ. Altered endothelial function in lambs with pulmonary hypertension and acute lung injury. Pediatr Pulmonol. 1999;27(3):147–156. doi: 10.1002/(sici)1099-0496(199903)27:3<147::aid-ppul1>3.0.co;2-p. [DOI] [PubMed] [Google Scholar]
  • 49.Mata-Greenwood E, Meyrick B, Steinhorn RH, Fineman JR, Black SM. Alterations in TGF-beta1 expression in lambs with increased pulmonary blood flow and pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2003;285(1):L209–L221. doi: 10.1152/ajplung.00171.2002. [DOI] [PubMed] [Google Scholar]
  • 50.Ovadia B, Reinhartz O, Fitzgerald R, Bekker JM, Johengen MJ, Azakie A, et al. Alterations in ET-1, not nitric oxide, in 1-week-old lambs with increased pulmonary blood flow. Am J Physiol Heart Circ Physiol. 2003;284(2):H480–H490. doi: 10.1152/ajpheart.00493.2002. [DOI] [PubMed] [Google Scholar]
  • 51.Reddy VM, Meyrick B, Wong J, Khoor A, Liddicoat JR, Hanley FL, et al. In utero placement of aortopulmonary shunts. A model of postnatal pulmonary hypertension with increased pulmonary blood flow in lambs. Circulation. 1995;92(3):606–613. doi: 10.1161/01.cir.92.3.606. [DOI] [PubMed] [Google Scholar]
  • 52.Steinhorn RH, Fineman JR. The pathophysiology of pulmonary hypertension in congenital heart disease. Artif Organs. 1999;23(11):970–974. doi: 10.1046/j.1525-1594.1999.06447.x. [DOI] [PubMed] [Google Scholar]
  • 53.Steinhorn RH, Russell JA, Lakshminrusimha S, Gugino SF, Black SM, Fineman JR. Altered endothelium-dependent relaxations in lambs with high pulmonary blood flow and pulmonary hypertension. Am J Physiol Heart Circ Physiol. 2001;280(1):H311–H317. doi: 10.1152/ajpheart.2001.280.1.H311. [DOI] [PubMed] [Google Scholar]
  • 54.Wong J, Reddy VM, Hendricks-Munoz K, Liddicoat JR, Gerrets R, Fineman JR. Endothelin-1 vasoactive responses in lambs with pulmonary hypertension and increased pulmonary blood flow. Am J Physiol. 1995;269(6 Pt 2):H1965–H1972. doi: 10.1152/ajpheart.1995.269.6.H1965. [DOI] [PubMed] [Google Scholar]
  • 55.Abman SH, Shanley PF, Accurso FJ. Failure of postnatal adaptation of the pulmonary circulation after chronic intrauterine pulmonary hypertension in fetal lambs. J Clin Invest. 1989;83(6):1849–1858. doi: 10.1172/JCI114091. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Haworth SG, Reid L. Persistent fetal circulation: newly recognized structural features. J Pediatr. 1976;88(4 Pt 1):614–620. doi: 10.1016/s0022-3476(76)80021-2. [DOI] [PubMed] [Google Scholar]
  • 57.Murphy JD, Rabinovitch M, Goldstein JD, Reid LM. The structural basis of persistent pulmonary hypertension of the newborn infant. J Pediatr. 1981;98(6):962–967. doi: 10.1016/s0022-3476(81)80605-1. [DOI] [PubMed] [Google Scholar]
  • 58.Oishi P, Fineman JR. Pharmacologic therapy for persistent pulmonary hypertension of the newborn: as "poly’’ as the disease itself. Pediatr Crit Care Med. 2004;5(1):94–96. doi: 10.1097/01.PCC.0000103193.92228.39. [DOI] [PubMed] [Google Scholar]
  • 59.Reid LM. Structure and function in pulmonary hypertension. New perceptions. Chest. 1986;89(2):279–288. doi: 10.1378/chest.89.2.279. [DOI] [PubMed] [Google Scholar]
  • 60.Rosenberg AA, Kennaugh J, Koppenhafer SL, Loomis M, Chatfield BA, Abman SH. Elevated immunoreactive endothelin-1 levels in newborn infants with persistent pulmonary hypertension. J Pediatr. 1993;123(1):109–114. doi: 10.1016/s0022-3476(05)81552-5. [DOI] [PubMed] [Google Scholar]
  • 61.Adnot S, Raffestin B, Eddahibi S, Braquet P, Chabrier PE. Loss of endothelium-dependent relaxant activity in the pulmonary circulation of rats exposed to chronic hypoxia. J Clin Invest. 1991;87(1):155–162. doi: 10.1172/JCI114965. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, Groves BM, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med. 1992;327(2):70–75. doi: 10.1056/NEJM199207093270202. [DOI] [PubMed] [Google Scholar]
  • 63.Jernigan NL, Walker BR, Resta TC. Pulmonary PKG-1 is upregulated following chronic hypoxia. Am J Physiol Lung Cell Mol Physiol. 2003;285(3):L634–L642. doi: 10.1152/ajplung.00328.2002. [DOI] [PubMed] [Google Scholar]
  • 64.Steinhorn RH, Morin FC, 3rd, Fineman JR. Models of persistent pulmonary hypertension of the newborn (PPHN) and the role of cyclic guanosine monophosphate (GMP) in pulmonary vasorelaxation. Semin Perinatol. 1997;21(5):393–408. doi: 10.1016/s0146-0005(97)80005-5. [DOI] [PubMed] [Google Scholar]
  • 65.Rudolph AM, Auld PA. Physical factors affecting normal and serotonin-constricted pulmonary vessels. Am J Physiol. 1960;198:864–872. doi: 10.1152/ajplegacy.1960.198.4.864. [DOI] [PubMed] [Google Scholar]
  • 66.Rudolph AM, Yuan S. Response of the pulmonary vasculature to hypoxia and H+ ion concentration changes. J Clin Invest. 1966;45(3):399–411. doi: 10.1172/JCI105355. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Marshall C, Marshall B. Site and sensitivity for stimulation of hypoxic pulmonary vasoconstriction. J Appl Physiol. 1983;55(3):711–716. doi: 10.1152/jappl.1983.55.3.711. [DOI] [PubMed] [Google Scholar]
  • 68.Custer JR, Hales CA. Influence of alveolar oxygen on pulmonary vasoconstriction in newborn lambs versus sheep. Am Rev Respir Dis. 1985;132(2):326–331. doi: 10.1164/arrd.1985.132.2.326. [DOI] [PubMed] [Google Scholar]
  • 69.Cutaia M, Rounds S. Hypoxic pulmonary vasoconstriction. Physiologic significance, mechanism, and clinical relevance. Chest. 1990;97(3):706–718. doi: 10.1378/chest.97.3.706. [DOI] [PubMed] [Google Scholar]
  • 70.Moudgil R, Michelakis ED, Archer SL. Hypoxic pulmonary vasoconstriction. J Appl Physiol. 2005;98(1):390–403. doi: 10.1152/japplphysiol.00733.2004. [DOI] [PubMed] [Google Scholar]
  • 71.Schreiber MD, Heymann MA, Soifer SJ. Increased arterial pH, not decreased PaCO2, attenuates hypoxia-induced pulmonary vasoconstriction in newborn lambs. Pediatr Res. 1986;20(2):113–117. doi: 10.1203/00006450-198602000-00003. [DOI] [PubMed] [Google Scholar]
  • 72.Cartwright D, Gregory GA, Lou H, Heyman MA. The effect of hypocarbia on the cardiovascular system of puppies. Pediatr Res. 1984;18(8):685–690. doi: 10.1203/00006450-198408000-00001. [DOI] [PubMed] [Google Scholar]
  • 73.Cornfield DN, Resnik ER, Herron JM, Reinhartz O, Fineman JR. Pulmonary vascular K+ channel expression and vasoreactivity in a model of congenital heart disease. Am J Physiol Lung Cell Mol Physiol. 2002;283(6):L1210–L1219. doi: 10.1152/ajplung.00428.2001. [DOI] [PubMed] [Google Scholar]
  • 74.Colebatch HJ, Dawes GS, Goodwin JW, Nadeau RA. The nervous control of the circulation in the foetal and newly expanded lungs of the lamb. J Physiol. 1965;178(3):544–562. doi: 10.1113/jphysiol.1965.sp007641. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Rudolph AM, Heyman MA, Lewis AB. Physiology and pharmacology of the pulmonary circulation in the fetus and newborn. In: Hodson WA, ed. Lung Biology and Disease. Development of the Lung. New York: Dekker.
  • 76.Roos A. Poiseuille’s law and its limitations in vascular systems. Med Thorac. 1962;19:224–238. doi: 10.1159/000192223. [DOI] [PubMed] [Google Scholar]
  • 77.Caro CG. Mechanics of the pulmonary circulation. In: Caro CG, editor. Advances in Pulmonary Physiology. London: Edwin Arnold; 1966. [Google Scholar]
  • 78.Prandtl L, Tietjens OG. Applied Hydro- and Aeromechanics. New York: Dover; 1957. [Google Scholar]
  • 79.Rudolph AM. Congenital Diseases of the Heart: Clinical-Physiological Considerations. 2nd ed. Armonk, NY: Futura; 2001. [Google Scholar]
  • 80.Agarwal JB, Paltoo R, Palmer WH. Relative viscosity of blood at varying hematocrits in pulmonary circulation. J Appl Physiol. 1970;29(6):866–871. doi: 10.1152/jappl.1970.29.6.866. [DOI] [PubMed] [Google Scholar]
  • 81.Benis AM, Usami S, Chien S. Effect of hematocrit and inertial losses on pressure-flow relations in the isolated hindpaw o the dog. Circ Res. 1970;27(6):1047–1068. doi: 10.1161/01.res.27.6.1047. [DOI] [PubMed] [Google Scholar]
  • 82.Culver BH, Butler J. Mechanical influences on the pulmonary microcirculation. Annu Rev Physiol. 1980;42:187–198. doi: 10.1146/annurev.ph.42.030180.001155. [DOI] [PubMed] [Google Scholar]
  • 83.Permutt S, Caldini P, Maseri A. Recruitment vs. distensibility in the pulmonary vascular bed. In: Fishman AP, Hecht HH, editors. The Pulmonary Circulation and Interstitial Space. Chicago: University of Chicago Press; 1969. [Google Scholar]
  • 84.Baile EM, Pare PD, Brooks LA, Hogg JC. Relationship between regional lung volume and regional pulmonary vascular resistance. J Appl Physiol. 1982;52(4):914–920. doi: 10.1152/jappl.1982.52.4.914. [DOI] [PubMed] [Google Scholar]
  • 85.Whittenberger JL, Mc GM, Berglund E, Borst HG. Influence of state of inflation of the lung on pulmonary vascular resistance. J Appl Physiol. 1960;15:878–882. doi: 10.1152/jappl.1960.15.5.878. [DOI] [PubMed] [Google Scholar]
  • 86.Bush PA, Gonzalez NE, Ignarro LJ. Biosynthesis of nitric oxide and citrulline from L-arginine by constitutive nitric oxide synthase present in rabbit corpus cavernosum. Biochem Biophys Res Commun. 1992;186(1):308–314. doi: 10.1016/s0006-291x(05)80808-3. [DOI] [PubMed] [Google Scholar]
  • 87.Ignarro LJ, Byrns RE, Buga GM, Wood KS. Endothelium-derived relaxing factor from pulmonary artery and vein possesses pharmacologic and chemical properties identical to those of nitric oxide radical. Circ Res. 1987;61(6):866–879. doi: 10.1161/01.res.61.6.866. [DOI] [PubMed] [Google Scholar]
  • 88.Ignarro LJ, Ross G, Tillisch J. Pharmacology of endothelium- derived nitric oxide and nitrovasodilators. West J Med. 1991;154(1):51–62. [PMC free article] [PubMed] [Google Scholar]
  • 89.Ignarro LJ, Harbison RG, Wood KS, Kadowitz PJ. Activation of purified soluble guanylate cyclase by endothelium-derived relaxing factor from intrapulmonary artery and vein: stimulation by acetylcholine, bradykinin and arachidonic acid. J Pharmacol Exp Ther. 1986;237(3):893–900. [PubMed] [Google Scholar]
  • 90.Murad F. Cyclic guanosine monophosphate as a mediator of vasodilation. J Clin Invest. 1986;78(1):1–5. doi: 10.1172/JCI112536. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 91.Mulsch A, Bassenge E, Busse R. Nitric oxide synthesis in endothelial cytosol: evidence for a calcium-dependent and a calcium-independent mechanism. Naunyn Schmiedebergs Arch Pharmacol. 1989;340(6 Pt 2):767–770. doi: 10.1007/BF00169688. [DOI] [PubMed] [Google Scholar]
  • 92.Brashers VL, Peach MJ, Rose CE., Jr Augmentation of hypoxic pulmonary vasoconstriction in the isolated perfused rat lung by in vitro antagonists of endothelium-dependent relaxation. J Clin Invest. 1988;82(5):1495–1502. doi: 10.1172/JCI113757. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 93.Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature. 1990;348(6303):730–732. doi: 10.1038/348730a0. [DOI] [PubMed] [Google Scholar]
  • 94.Sakurai T, Yanagisawa M, Takuwa Y, Miyazaki H, Kimura S, Goto K, et al. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature. 1990;348(6303):732–735. doi: 10.1038/348732a0. [DOI] [PubMed] [Google Scholar]
  • 95.Rubanyi GM, editor. Endothelin. New York: Oxford University Press for the American Physiological Society; 1992. [Google Scholar]
  • 96.Vane JR, Anggard EE, Botting RM. Regulatory functions of the vascular endothelium. N Engl J Med. 1990;323(1):27–36. doi: 10.1056/NEJM199007053230106. [DOI] [PubMed] [Google Scholar]
  • 97.Faraci FM, Heistad DD. Regulation of the cerebral circulation: role of endothelium and potassium channels. Physiol Rev. 1998;78(1):53–97. doi: 10.1152/physrev.1998.78.1.53. [DOI] [PubMed] [Google Scholar]
  • 98.Rabinovitch M, Bothwell T, Hayakawa BN, Williams WG, Trusler GA, Rowe RD, et al. Pulmonary artery endothelial abnormalities in patients with congenital heart defects and pulmonary hypertension. A correlation of light with scanning electron microscopy and transmission electron microscopy. Lab Invest. 1986;55(6):632–653. [PubMed] [Google Scholar]
  • 99.Dinh Xuan AT, Higenbottam TW, Clelland C, Pepke-Zaba J, Cremona G, Wallwork J. Impairment of pulmonary endothelium-dependent relaxation in patients with Eisenmenger’s syndrome. Br J Pharmacol. 1990;99(1):9–10. doi: 10.1111/j.1476-5381.1990.tb14643.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 100.Meyrick B, Gamble W, Reid L. Development of Crotalaria pulmonary hypertension: hemodynamic and structural study. Am J Physiol. 1980;239(5):H692–H702. doi: 10.1152/ajpheart.1980.239.5.H692. [DOI] [PubMed] [Google Scholar]
  • 101.Yoshibayashi M, Nishioka K, Nakao K, Saito Y, Matsumura M, Ueda T, et al. Plasma endothelin concentrations in patients with pulmonary hypertension associated with congenital heart defects. Evidence for increased production of endothelin in pulmonary circulation. Circulation. 1991;84(6):2280–2285. doi: 10.1161/01.cir.84.6.2280. [DOI] [PubMed] [Google Scholar]
  • 102.Lane KB, Machado RD, Pauciulo MW, Thomson JR, Phillips JA, 3rd, Loyd JE, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. Nat Genet. 2000;26(1):81–84. doi: 10.1038/79226. [DOI] [PubMed] [Google Scholar]
  • 103.Thomson JR, Machado RD, Pauciulo MW, Morgan NV, Humbert M, Elliott GC, et al. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family. J Med Genet. 2000;37(10):741–745. doi: 10.1136/jmg.37.10.741. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 104.Newman JH, Wheeler L, Lane KB, Loyd E, Gaddipati R, Phillips JA, 3rd, et al. Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred. N Engl J Med. 2001;345(5):319–324. doi: 10.1056/NEJM200108023450502. [DOI] [PubMed] [Google Scholar]
  • 105.Humbert M, Deng Z, Simonneau G, Barst RJ, Sitbon O, Wolf M, et al. BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives. Eur Respir J. 2002;20(3):518–523. doi: 10.1183/09031936.02.01762002. [DOI] [PubMed] [Google Scholar]
  • 106.Rabinovitch M, Haworth SG, Castaneda AR, Nadas AS, Reid LM. Lung biopsy in congenital heart disease: a morphometric approach to pulmonary vascular disease. Circulation. 1978;58(6):1107–1122. doi: 10.1161/01.cir.58.6.1107. [DOI] [PubMed] [Google Scholar]
  • 107.Meyrick B, Reid L. Ultrastructural findings in lung biopsy material from children with congenital heart defects. Am J Pathol. 1980;101(3):527–542. [PMC free article] [PubMed] [Google Scholar]
  • 108.Hislop A, Haworth SG, Shinebourne EA, Reid L. Quantitative structural analysis of pulmonary vessels in isolated ventricular septal defect in infancy. Br Heart J. 1975;37(10):1014–1021. doi: 10.1136/hrt.37.10.1014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 109.Haworth SG. Pulmonary vascular disease in different types of congenital heart disease. Implications for interpretation of lung biopsy findings in early childhood. Br Heart J. 1984;52(5):557–571. doi: 10.1136/hrt.52.5.557. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 110.Hoffman JI, Rudolph AM, Heymann MA. Pulmonary vascular disease with congenital heart lesions: pathologic features and causes. Circulation. 1981;64(5):873–877. doi: 10.1161/01.cir.64.5.873. [DOI] [PubMed] [Google Scholar]
  • 111.Burrows FA, Klinck JR, Rabinovitch M, Bohn DJ. Pulmonary hypertension in children: perioperative management. Can Anaesth Soc J. 1986;33(5):606–628. doi: 10.1007/BF03014268. [DOI] [PubMed] [Google Scholar]
  • 112.Wheller J, George BL, Mulder DG, Jarmakani JM. Diagnosis and management of postoperative pulmonary hypertensive crisis. Circulation. 1979;60(7):1640–1644. doi: 10.1161/01.cir.60.7.1640. [DOI] [PubMed] [Google Scholar]
  • 113.Rowe RD, Hoffman T. Transient myocardial ischemia of the newborn infant: a form of severe cardiorespiratory distress in full-term infants. J Pediatr. 1972;81(2):243–250. doi: 10.1016/s0022-3476(72)80290-7. [DOI] [PubMed] [Google Scholar]
  • 114.Turner-Gomes SO, Izukawa T, Rowe RD. Persistence of atrioventricular valve regurgitation and electrocardiographic abnormalities following transient myocardial ischemia of the newborn. Pediatr Cardiol. 1989;10(4):191–194. doi: 10.1007/BF02083291. [DOI] [PubMed] [Google Scholar]
  • 115.Bancalari E, Jesse MJ, Gelband H, Garcia O. Lung mechanics in congenital heart disease with increased and decreased pulmonary blood flow. J Pediatr. 1977;90(2):192–195. doi: 10.1016/s0022-3476(77)80628-8. [DOI] [PubMed] [Google Scholar]
  • 116.Day RW, Allen EM, Witte MK. A randomized, controlled study of the 1-hour and 24-hour effects of inhaled nitric oxide therapy in children with acute hypoxemic respiratory failure. Chest. 1997;112(5):1324–1331. doi: 10.1378/chest.112.5.1324. [DOI] [PubMed] [Google Scholar]
  • 117.Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. The Neonatal Inhaled Nitric Oxide Study Group. N Engl J Med. 1997;336(9):597–604. doi: 10.1056/NEJM199702273360901. [DOI] [PubMed] [Google Scholar]
  • 118.Atz AM, Wessel DL. Inhaled nitric oxide in the neonate with cardiac disease. Semin Perinatol. 1997;21(5):441–155. doi: 10.1016/s0146-0005(97)80009-2. [DOI] [PubMed] [Google Scholar]
  • 119.Clark RH, Kueser TJ, Walker MW, Southgate WM, Huckaby JL, Perez JA, et al. Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. Clinical Inhaled Nitric Oxide Research Group. N Engl J Med. 2000;342(7):469–474. doi: 10.1056/NEJM200002173420704. [DOI] [PubMed] [Google Scholar]
  • 120.Dellinger RP, Zimmerman JL, Taylor RW, Straube RC, Hauser DL, Criner GJ, et al. Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: results of a randomized phase II trial. Inhaled Nitric Oxide in ARDS Study Group. Crit Care Med. 1998;26(1):15–23. doi: 10.1097/00003246-199801000-00011. [DOI] [PubMed] [Google Scholar]
  • 121.Dobyns EL, Cornfield DN, Anas NG, Fortenberry JD, Tasker RC, Lynch A, et al. Multicenter randomized controlled trial of the effects of inhaled nitric oxide therapy on gas exchange in children with acute hypoxemic respiratory failure. J Pediatr. 1999;134(4):406–412. doi: 10.1016/s0022-3476(99)70196-4. [DOI] [PubMed] [Google Scholar]
  • 122.Fineman JR, Zwass MS. Inhaled nitric oxide therapy for persistent pulmonary hypertension of the newborn. Acta Paediatr Jpn. 1995;37(4):425–430. doi: 10.1111/j.1442-200x.1995.tb03350.x. [DOI] [PubMed] [Google Scholar]
  • 123.Karamanoukian HL, Glick PL, Zayek M, Steinhorn RH, Zwass MS, Fineman JR, et al. Inhaled nitric oxide in congenital hypoplasia of the lungs due to diaphragmatic hernia or oligohydramnios. Pediatrics. 1994;94(5):715–718. [PubMed] [Google Scholar]
  • 124.Kinsella JP, Truog WE, Walsh WF, Goldberg RN, Bancalari E, Mayock DE, et al. Randomized, multicenter trial of inhaled nitric oxide and high-frequency oscillatory ventilation in severe, persistent pulmonary hypertension of the newborn. J Pediatr. 1997;131(1 Pt 1):55–62. doi: 10.1016/s0022-3476(97)70124-0. [DOI] [PubMed] [Google Scholar]
  • 125.Lunn RJ. Inhaled nitric oxide therapy. Mayo Clin Proc. 1995;70(3):247–255. doi: 10.4065/70.3.247. [DOI] [PubMed] [Google Scholar]
  • 126.Roberts JD, Jr., Fineman JR, Morin FC, 3rd, Shaul PW, Rimar S, Schreiber MD, et al. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. The Inhaled Nitric Oxide Study Group. N Engl J Med. 1997;336(9):605–610. doi: 10.1056/NEJM199702273360902. [DOI] [PubMed] [Google Scholar]
  • 127.Russell IA, Zwass MS, Fineman JR, Balea M, Rouine-Rapp K, Brook M, et al. The effects of inhaled nitric oxide on postoperative pulmonary hypertension in infants and children undergoing surgical repair of congenital heart disease. Anesth Analg. 1998;87(1):46–51. doi: 10.1097/00000539-199807000-00011. [DOI] [PubMed] [Google Scholar]
  • 128.Schreiber MD, Gin-Mestan K, Marks JD, Huo D, Lee G, Srisuparp P. Inhaled nitric oxide in premature infants with the respiratory distress syndrome. N Engl J Med. 2003;349(22):2099–2107. doi: 10.1056/NEJMoa031154. [DOI] [PubMed] [Google Scholar]
  • 129.Heidersbach RS, Johengen MJ, Bekker JM, Fineman JR. Inhaled nitric oxide, oxygen, and alkalosis: dose-response interactions in a lamb model of pulmonary hypertension. Pediatr Pulmonol. 1999;28(1):3–11. doi: 10.1002/(sici)1099-0496(199907)28:1<3::aid-ppul2>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  • 130.Stephenson LW, Edmunds LH, Jr., Raphaely R, Morrison DF, Hoffman WS, Rubis LJ. Effects of nitroprusside and dopamine on pulmonary arterial vasculature in children after cardiac surgery. Circulation. 1979;60(2 Pt 2):104–110. doi: 10.1161/01.cir.60.2.104. [DOI] [PubMed] [Google Scholar]
  • 131.Rubis LJ, Stephenson LW, Johnston MR, Nagaraj S, Edmunds LH., Jr Comparison of effects of prostaglandin E1 and nitroprusside on pulmonary vascular resistance in children after open-heart surgery. Ann Thorac Surg. 1981;32(6):563–570. doi: 10.1016/s0003-4975(10)61799-7. [DOI] [PubMed] [Google Scholar]
  • 132.Wimmer M, Schlemmer M, Ebner F. Hemodynamic effects of nife-dipine and oxygen in children with pulmonary hypertension. Cardiovasc Drugs Ther. 1988;2(5):661–668. doi: 10.1007/BF00054206. [DOI] [PubMed] [Google Scholar]
  • 133.Bush A, Busst C, Booth K, Knight WB, Shinebourne EA. Does prostacyclin enhance the selective pulmonary vasodilator effect of oxygen in children with congenital heart disease? Circulation. 1986;74(1):135–144. doi: 10.1161/01.cir.74.1.135. [DOI] [PubMed] [Google Scholar]
  • 134.Uglov FG, Davydenko VV, Orlovskii PI, Grigor’ev EE, Bushmarin ON. [Intravascular hemolysis in patients with artificial heart valves] Vestn Khir Im I I Grek. 1986;136(4):135–141. [PubMed] [Google Scholar]
  • 135.Weesner KM. Hemodynamic effects of prostaglandin E1 in patients with congenital heart disease and pulmonary hypertension. Cathet Cardiovasc Diagn. 1991;24(1):10–15. doi: 10.1002/ccd.1810240104. [DOI] [PubMed] [Google Scholar]
  • 136.Kermode J, Butt W, Shann F. Comparison between prostaglandin E1 and epoprostenol (prostacyclin) in infants after heart surgery. Br Heart J. 1991;66(2):175–178. doi: 10.1136/hrt.66.2.175. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 137.Brook MM, Fineman JR, Bolinger AM, Wong AF, Heymann MA, Soifer SJ. Use of ATP-MgCl2 in the evaluation and treatment of children with pulmonary hypertension secondary to congenital heart defects. Circulation. 1994;90(3):1287–1293. doi: 10.1161/01.cir.90.3.1287. [DOI] [PubMed] [Google Scholar]
  • 138.Stevenson DK, Kasting DS, Darnall RA, Jr, Ariagno RL, Johnson JD, Malachowski N, et al. Refractory hypoxemia associated with neonatal pulmonary disease: the use and limitations of tolazoline. J Pediatr. 1979;95(4):595–599. doi: 10.1016/s0022-3476(79)80777-5. [DOI] [PubMed] [Google Scholar]
  • 139.Tripp ME, Drummond WH, Heymann MA, Rudolph AM. Hemodynamic effects of pulmonary arterial infusion of vasodilators in newborn lambs. Pediatr Res. 1980;14(12):1311–1315. doi: 10.1203/00006450-198012000-00007. [DOI] [PubMed] [Google Scholar]
  • 140.Starling MB, Neutze JM, Elliott RL, Elliott RB. Comparative studies on the hemodynamic effects of prostaglandin E1 prostacyclin, and tolazoline upon elevated pulmonary vascular resistance in neonatal swine. Prostaglandins Med. 1981;7(5):349–361. doi: 10.1016/0161-4630(81)90024-0. [DOI] [PubMed] [Google Scholar]
  • 141.Radermacher P, Huet Y, Pluskwa F, Herigault R, Mal H, Teisseire B, et al. Comparison of ketanserin and sodium nitroprusside in patients with severe ARDS. Anesthesiology. 1988;68(1):152–157. doi: 10.1097/00000542-198801000-00030. [DOI] [PubMed] [Google Scholar]
  • 142.Radermacher P, Santak B, Becker H, Falke KJ. Prostaglandin E1 and nitroglycerin reduce pulmonary capillary pressure but worsen ventilation-perfusion distributions in patients with adult respiratory distress syndrome. Anesthesiology. 1989;70(4):601–606. doi: 10.1097/00000542-198904000-00008. [DOI] [PubMed] [Google Scholar]
  • 143.Vlahakes GJ, Turley K, Hoffman JI. The pathophysiology of failure in acute right ventricular hypertension: hemodynamic and biochemical correlations. Circulation. 1981;63(1):87–95. doi: 10.1161/01.cir.63.1.87. [DOI] [PubMed] [Google Scholar]
  • 144.Melot C, Lejeune P, Leeman M, Moraine JJ, Naeije R. Prostaglandin E1 in the adult respiratory distress syndrome. Benefit for pulmonary hypertension and cost for pulmonary gas exchange. Am Rev Respir Dis. 1989;139(1):106–110. doi: 10.1164/ajrccm/139.1.106. [DOI] [PubMed] [Google Scholar]
  • 145.Radermacher P, Santak B, Wust HJ, Tarnow J, Falke KJ. Prostacyclin for the treatment of pulmonary hypertension in the adult respiratory distress syndrome: effects on pulmonary capillary pressure and ventilation-perfusion distributions. Anesthesiology. 1990;72(2):238–244. doi: 10.1097/00000542-199002000-00005. [DOI] [PubMed] [Google Scholar]
  • 146.De Wet CJ, Affleck DG, Jacobsohn E, Avidan MS, Tymkew H, Hill LL, et al. Inhaled prostacyclin is safe, effective, and affordable in patients with pulmonary hypertension, right heart dysfunction, and refractory hypoxemia after cardiothoracic surgery. J Thorac Cardiovasc Surg. 2004;127(4):1058–1067. doi: 10.1016/j.jtcvs.2003.11.035. [DOI] [PubMed] [Google Scholar]
  • 147.Hache M, Denault A, Belisle S, Robitaille D, Couture P, Sheridan P, et al. Inhaled epoprostenol (prostacyclin) and pulmonary hypertension before cardiac surgery. J Thorac Cardiovasc Surg. 2003;125(3):642–649. doi: 10.1067/mtc.2003.107. [DOI] [PubMed] [Google Scholar]
  • 148.Kelly LK, Porta NF, Goodman DM, Carroll CL, Steinhorn RH. Inhaled prostacyclin for term infants with persistent pulmonary hypertension refractory to inhaled nitric oxide. J Pediatr. 2002;141(6):830–832. doi: 10.1067/mpd.2002.129849. [DOI] [PubMed] [Google Scholar]
  • 149.Weston MW, Isaac BF, Crain C. The use of inhaled prostacyclin in nitroprusside-resistant pulmonary artery hypertension. J Heart Lung Transplant. 2001;20(12):1340–1344. doi: 10.1016/s1053-2498(01)00320-5. [DOI] [PubMed] [Google Scholar]
  • 150.Hache M, Denault AY, Belisle S, Couture P, Babin D, Tetrault F, et al. Inhaled prostacyclin (PGI2) is an effective addition to the treatment of pulmonary hypertension and hypoxia in the operating room and intensive care unit. Can J Anaesth. 2001;48(9):924–929. doi: 10.1007/BF03017361. [DOI] [PubMed] [Google Scholar]
  • 151.Fiser SM, Cope JT, Kron IL, Kaza AK, Long SM, Kern JA, et al. Aerosolized prostacyclin (epoprostenol) as an alternative to inhaled nitric oxide for patients with reperfusion injury after lung transplantation. J Thorac Cardiovasc Surg. 2001;121(5):981–982. doi: 10.1067/mtc.2001.115668. [DOI] [PubMed] [Google Scholar]
  • 152.Della Rocca G, Coccia C, Costa MG, Pompei L, Di Marco P, Vizza CD, et al. Inhaled aerosolized prostacyclin and pulmonary hypertension during anesthesia for lung transplantation. Transplant Proc. 2001;33(1–2):1634–1636. doi: 10.1016/s0041-1345(00)02623-3. [DOI] [PubMed] [Google Scholar]
  • 153.Abe Y, Tatsumi K, Sugito K, Ikeda Y, Kimura H, Kuriyama T. Effects of inhaled prostacyclin analogue on chronic hypoxic pulmonary hypertension. J Cardiovasc Pharmacol. 2001;37(3):239–251. doi: 10.1097/00005344-200103000-00002. [DOI] [PubMed] [Google Scholar]
  • 154.van Heerden PV, Barden A, Michalopoulos N, Bulsara MK, Roberts BL. Dose-response to inhaled aerosolized prostacyclin for hypoxemia due to ARDS. Chest. 2000;117(3):819–827. doi: 10.1378/chest.117.3.819. [DOI] [PubMed] [Google Scholar]
  • 155.Max M, Rossaint R. Inhaled prostacyclin in the treatment of pulmonary hypertension. Eur J Pediatr. 1999;158(Suppl 1):S23–S26. doi: 10.1007/pl00014316. [DOI] [PubMed] [Google Scholar]
  • 156.Olschewski H, Ghofrani HA, Walmrath D, Schermuly R, Temmesfeld-Wollbruck B, Grimminger F, et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med. 1999;160(2):600–607. doi: 10.1164/ajrccm.160.2.9810008. [DOI] [PubMed] [Google Scholar]
  • 157.Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev. 1995;75(4):725–748. doi: 10.1152/physrev.1995.75.4.725. [DOI] [PubMed] [Google Scholar]
  • 158.Kato R, Sato J, Nishino T. Milrinone decreases both pulmonary arterial and venous resistances in the hypoxic dog. Br J Anaesth. 1998;81(6):920–924. doi: 10.1093/bja/81.6.920. [DOI] [PubMed] [Google Scholar]
  • 159.Chen EP, Bittner HB, Davis RD, Jr, Van Trigt P., 3rd Milrinone improves pulmonary hemodynamics and right ventricular function in chronic pulmonary hypertension. Ann Thorac Surg. 1997;63(3):814–821. doi: 10.1016/s0003-4975(97)00011-8. [DOI] [PubMed] [Google Scholar]
  • 160.Chen EP, Bittner HB, Davis RD, Van Trigt P. Hemodynamic and inotropic effects of milrinone after heart transplantation in the setting of recipient pulmonary hypertension. J Heart Lung Transplant. 1998;17(7):669–678. [PubMed] [Google Scholar]
  • 161.Chang AC, Atz AM, Wernovsky G, Burke RP, Wessel DL. Milrinone: systemic and pulmonary hemodynamic effects in neonates after cardiac surgery. Crit Care Med. 1995;23(11):1907–1914. doi: 10.1097/00003246-199511000-00018. [DOI] [PubMed] [Google Scholar]
  • 162.Hoffman TM, Wernovsky G, Atz AM, Kulik TJ, Nelson DP, Chang AC, et al. Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease. Circulation. 2003;107(7):996–1002. doi: 10.1161/01.cir.0000051365.81920.28. [DOI] [PubMed] [Google Scholar]
  • 163.Watanabe H, Ohashi K, Takeuchi K, Yamashita K, Yokoyama T, Tran QK, et al. Sildenafil for primary and secondary pulmonary hypertension. Clin Pharmacol Ther. 2002;71(5):398–402. doi: 10.1067/mcp.2002.123554. [DOI] [PubMed] [Google Scholar]
  • 164.Humpl T, Reyes JT, Holtby H, Stephens D, Adatia I. Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study. Circulation. 2005;111(24):3274–3280. doi: 10.1161/CIRCULATIONAHA.104.473371. [DOI] [PubMed] [Google Scholar]
  • 165.Shekerdemian LS, Ravn HB, Penny DJ. Interaction between inhaled nitric oxide and intravenous sildenafil in a porcine model of meconium aspiration syndrome. Pediatr Res. 2004;55(3):413–418. doi: 10.1203/01.PDR.0000112033.81970.C2. [DOI] [PubMed] [Google Scholar]
  • 166.Stocker C, Penny DJ, Brizard CP, Cochrane AD, Soto R, Shekerdemian LS. Intravenous sildenafil and inhaled nitric oxide: a randomised trial in infants after cardiac surgery. Intensive Care Med. 2003;29(11):1996–2003. doi: 10.1007/s00134-003-2016-4. [DOI] [PubMed] [Google Scholar]
  • 167.Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo- controlled study. Lancet. 2001;358(9288):1119–1123. doi: 10.1016/S0140-6736(01)06250-X. [DOI] [PubMed] [Google Scholar]
  • 168.Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346(12):896–903. doi: 10.1056/NEJMoa012212. [DOI] [PubMed] [Google Scholar]
  • 169.Kouchoukos NT, Blackstone EH, Kirklin JW. Surgical implications of pulmonary hypertension in congenital heart disease. Adv Cardiol. 1978;22:225–231. doi: 10.1159/000401033. [DOI] [PubMed] [Google Scholar]
  • 170.Mentzer RM, Alegre CA, Nolan SP. The effects of dopamine and isoproterenol on the pulmonary circulation. J Thorac Cardiovasc Surg. 1976;71(6):807–814. [PubMed] [Google Scholar]
  • 171.Holloway EL, Polumbo RA, Harrison DC. Acute circulatory effects of dopamine in patients with pulmonary hypertension. Br Heart J. 1975;37(5):482–485. doi: 10.1136/hrt.37.5.482. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 172.Martinez AM, Padbury JF, Thio S. Dobutamine pharmacokinetics and cardiovascular responses in critically ill neonates. Pediatrics. 1992;89(1):47–51. [PubMed] [Google Scholar]
  • 173.Perkin RM, Levin DL, Webb R, Aquino A, Reedy J. Dobutamine: a hemodynamic evaluation in children with shock. J Pediatr. 1982;100(6):977–983. doi: 10.1016/s0022-3476(82)80534-9. [DOI] [PubMed] [Google Scholar]
  • 174.Crowley MR, Fineman JR, Soifer SJ. Effects of vasoactive drugs on thromboxane A2 mimetic-induced pulmonary hypertension in new-born lambs. Pediatr Res. 1991;29(2):167–172. doi: 10.1203/00006450-199102000-00013. [DOI] [PubMed] [Google Scholar]
  • 175.Rozkovec A, Montanes P, Oakley CM. Factors that influence the outcome of primary pulmonary hypertension. Br Heart J. 1986;55(5):449–458. doi: 10.1136/hrt.55.5.449. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 176.Rich S, Lam W. Atrial septostomy as palliative therapy for refractory primary pulmonary hypertension. Am J Cardiol. 1983;51(9):1560–1561. doi: 10.1016/0002-9149(83)90678-1. [DOI] [PubMed] [Google Scholar]
  • 177.Mullins CE, Nihill MR, Vick GW, 3rd, Ludomirsky A, O’Laughlin MP, Bricker JT, et al. Double balloon technique for dilation of valvular or vessel stenosis in congenital and acquired heart disease. J Am Coll Cardiol. 1987;10(1):107–114. doi: 10.1016/s0735-1097(87)80168-7. [DOI] [PubMed] [Google Scholar]
  • 178.Hausknecht MJ, Sims RE, Nihill MR, Cashion WR. Successful palliation of primary pulmonary hypertension by atrial septostomy. Am J Cardiol. 1990;65(15):1045–1046. doi: 10.1016/0002-9149(90)91016-y. [DOI] [PubMed] [Google Scholar]
  • 179.Kerstein D, Levy PS, Hsu DT, Hordof AJ, Gersony WM, Barst RJ. Blade balloon atrial septostomy in patients with severe primary pulmonary hypertension. Circulation. 1995;91(7):2028–2035. doi: 10.1161/01.cir.91.7.2028. [DOI] [PubMed] [Google Scholar]
  • 180.Sandoval J, Gaspar J, Pulido T, Bautista E, Martinez-Guerra ML, Zeballos M, et al. Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilator treatment. J Am Coll Cardiol. 1998;32(2):297–304. doi: 10.1016/s0735-1097(98)00238-1. [DOI] [PubMed] [Google Scholar]
  • 181.Higenbottam T, Wheeldon D, Wells F, Wallwork J. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin) Lancet. 1984;1(8385):1046–1047. doi: 10.1016/s0140-6736(84)91452-1. [DOI] [PubMed] [Google Scholar]
  • 182.Barst RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS. Survival in primary pulmonary hypertension with long-term con-tinuous intravenous prostacyclin. Ann Intern Med. 1994;121(6):409–415. doi: 10.7326/0003-4819-121-6-199409150-00003. [DOI] [PubMed] [Google Scholar]
  • 183.Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med. 1996;334(5):296–302. doi: 10.1056/NEJM199602013340504. [DOI] [PubMed] [Google Scholar]
  • 184.Shapiro SM, Oudiz RJ, Cao T, Romano MA, Beckmann XJ, Georgiou D, et al. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol. 1997;30(2):343–349. doi: 10.1016/s0735-1097(97)00187-3. [DOI] [PubMed] [Google Scholar]
  • 185.McLaughlin VV, Genthner DE, Panella MM, Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med. 1998;338(5):273–277. doi: 10.1056/NEJM199801293380501. [DOI] [PubMed] [Google Scholar]
  • 186.Barst RJ, Maislin G, Fishman AP. Vasodilator therapy for primary pulmonary hypertension in children. Circulation. 1999;99(9):1197–1203. doi: 10.1161/01.cir.99.9.1197. [DOI] [PubMed] [Google Scholar]
  • 187.Widlitz A, Barst RJ. Pulmonary arterial hypertension in children. Eur Respir J. 2003;21(1):155–176. doi: 10.1183/09031936.03.00088302. [DOI] [PubMed] [Google Scholar]
  • 188.McLaughlin VV, Sitbon O, Badesch DB, Barst RJ, Black C, Galie N, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J. 2005;25(2):244–249. doi: 10.1183/09031936.05.00054804. [DOI] [PubMed] [Google Scholar]
  • 189.Keller RL, Hamrick SE, Kitterman JA, Fineman JR, Hawgood S. Treatment of rebound and chronic pulmonary hypertension with oral sildenafil in an infant with congenital diaphragmatic hernia. Pediatr Crit Care Med. 2004;5(2):184–187. doi: 10.1097/01.pcc.0000113266.26638.ad. [DOI] [PubMed] [Google Scholar]
  • 190.Bohn D, Tamura M, Perrin D, Barker G, Rabinovitch M. Ventilatory predictors of pulmonary hypoplasia in congenital diaphragmatic hernia, confirmed by morphologic assessment. J Pediatr. 1987;111(3):423–431. doi: 10.1016/s0022-3476(87)80474-2. [DOI] [PubMed] [Google Scholar]
  • 191.Naeye RL, Shochat SJ, Whitman V, Maisels MJ. Unsuspected pulmonary vascular abnormalities associated with diaphragmatic hernia. Pediatrics. 1976;58(6):902–906. [PubMed] [Google Scholar]
  • 192.Levin DL. Morphologic analysis of the pulmonary vascular bed in congenital left-sided diaphragmatic hernia. J Pediatr. 1978;92(5):805–809. doi: 10.1016/s0022-3476(78)80162-0. [DOI] [PubMed] [Google Scholar]
  • 193.Dibbins AW, Wiener ES. Mortality from neonatal diaphragmatic hernia. J Pediatr Surg. 1974;9(5):653–662. doi: 10.1016/0022-3468(74)90102-x. [DOI] [PubMed] [Google Scholar]
  • 194.Bloss RS, Aranda JV, Beardmore HE. Vasodilator response and prediction of survival in congenital diaphragmatic hernia. J Pediatr Surg. 1981;16(2):118–121. doi: 10.1016/s0022-3468(81)80335-1. [DOI] [PubMed] [Google Scholar]
  • 195.Fox WW, Gewitz MH, Dinwiddie R, Drummond WH, Peckham GJ. Pulmonary hypertension in the perinatal aspiration syndromes. Pediatrics. 1977;59(2):205–211. [PubMed] [Google Scholar]
  • 196.Shankaran S, Farooki ZQ, Desai R. beta-hemolytic streptococcal infection appearing as persistent fetal circulation. Am J Dis Child. 1982;136(8):725–727. doi: 10.1001/archpedi.1982.03970440069020. [DOI] [PubMed] [Google Scholar]
  • 197.Reece EA, Moya F, Yazigi R, Holford T, Duncan C, Ehrenkranz RA. Persistent pulmonary hypertension: assessment of perinatal risk factors. Obstet Gynecol. 1987;70(5):696–700. [PubMed] [Google Scholar]
  • 198.Soifer SJ, Kaslow D, Roman C, Heymann MA. Umbilical cord compression produces pulmonary hypertension in newborn lambs: a model to study the pathophysiology of persistent pulmonary hypertension in the newborn. J Dev Physiol. 1987;9(3):239–252. [PubMed] [Google Scholar]
  • 199.Levin DL, Mills LJ, Weinberg AG. Hemodynamic, pulmonary vascular, and myocardial abnormalities secondary to pharmacologic constriction of the fetal ductus arteriosus. A possible mechanism for persistent pulmonary hypertension and transient tricuspid insufficiency in the newborn infant. Circulation. 1979;60(2):360–364. doi: 10.1161/01.cir.60.2.360. [DOI] [PubMed] [Google Scholar]
  • 200.Morin FC., 3rd Ligating the ductus arteriosus before birth causes persistent pulmonary hypertension in the newborn lamb. Pediatr Res. 1989;25(3):245–250. doi: 10.1203/00006450-198903000-00005. [DOI] [PubMed] [Google Scholar]
  • 201.Wild LM, Nickerson PA, Morin FC., 3rd Ligating the ductus arteriosus before birth remodels the pulmonary vasculature of the lamb. Pediatr Res. 1989;25(3):251–257. doi: 10.1203/00006450-198903000-00006. [DOI] [PubMed] [Google Scholar]
  • 202.McQueston JA, Kinsella JP, Ivy DD, McMurtry IF, Abman SH. Chronic pulmonary hypertension in utero impairs endothelium-dependent vasodilation. Am J Physiol. 1995;268(1 Pt 2):H288–H294. doi: 10.1152/ajpheart.1995.268.1.H288. [DOI] [PubMed] [Google Scholar]
  • 203.Shaul PW, Yuhanna IS, German Z, Chen Z, Steinhorn RH, Morin FC., 3rd Pulmonary endothelial NO synthase gene expression is decreased in fetal lambs with pulmonary hypertension. Am J Physiol. 1997;272(5 Pt 1):L1005–L1012. doi: 10.1152/ajplung.1997.272.5.L1005. [DOI] [PubMed] [Google Scholar]
  • 204.Manchester D, Margolis HS, Sheldon RE. Possible association between maternal indomethacin therapy and primary pulmonary hypertension of the newborn. Am J Obstet Gynecol. 1976;126(4):467–469. doi: 10.1016/0002-9378(76)90640-2. [DOI] [PubMed] [Google Scholar]
  • 205.Levin DL, Fixler DE, Morriss FC, Tyson J. Morphologic analysis of the pulmonary vascular bed in infants exposed in utero to prostaglandin synthetase inhibitors. J Pediatr. 1978;92(3):478–483. doi: 10.1016/s0022-3476(78)80453-3. [DOI] [PubMed] [Google Scholar]
  • 206.Fox WW, Berman LS, Downes JJ, Jr, Peckham GJ. The therapeutic application of end-expiratory pressure in the meconium aspiration syndrome. Pediatrics. 1975;56(2):214–217. [PubMed] [Google Scholar]
  • 207.Truog WE, Lyrene RK, Standaert TA, Murphy J, Woodrum DE. Effects of PEEP and tolazoline infusion on respiratory and inert gas exchange in experimental meconium aspiration. J Pediatr. 1982;100(2):284–290. doi: 10.1016/s0022-3476(82)80656-2. [DOI] [PubMed] [Google Scholar]
  • 208.Auten RL, Notter RH, Kendig JW, Davis JM, Shapiro DL. Surfactant treatment of full-term newborns with respiratory failure. Pediatrics. 1991;87(1):101–107. [PubMed] [Google Scholar]
  • 209.Henry GW, Stevens DC, Schreiner RL, Grosfeld JL, Ballantine TV. Respiratory paralysis to improve oxygenation and mortality in large newborn infants with respiratory distress. J Pediatr Surg. 1979;14(6):761–767. doi: 10.1016/s0022-3468(79)80261-4. [DOI] [PubMed] [Google Scholar]
  • 210.Toomasian JM, Snedecor SM, Cornell RG, Cilley RE, Bartlett RH. National experience with extracorporeal membrane oxygenation for newborn respiratory failure. Data from 715 cases. ASAIO Trans. 1988;34(2):140–147. doi: 10.1097/00002480-198804000-00011. [DOI] [PubMed] [Google Scholar]
  • 211.O’Rourke PP, Crone RK, Vacanti JP, Ware JH, Lillehei CW, Parad RB, et al. Extracorporeal membrane oxygenation and conventional medical therapy in neonates with persistent pulmonary hypertension of the newborn: a prospective randomized study. Pediatrics. 1989;84(6):957–963. [PubMed] [Google Scholar]
  • 212.Meinert CL. Extracorporeal membrane oxygenation trials. Pediatrics. 1990;85(3):365–366. [PubMed] [Google Scholar]
  • 213.Bahrami KR, Van Meurs KP. ECMO for neonatal respiratory failure. Semin Perinatol. 2005;29(1):15–23. doi: 10.1053/j.semperi.2005.02.004. [DOI] [PubMed] [Google Scholar]
  • 214.Reid LM. The pulmonary circulation: remodeling in growth and disease. The 1978 J. Burns Amberson lecture. Am Rev Respir Dis. 1979;119(4):531–546. doi: 10.1164/arrd.1979.119.4.531. [DOI] [PubMed] [Google Scholar]
  • 215.Rabinovitch M, Keane JF, Norwood WI, Castaneda AR, Reid L. Vascular structure in lung tissue obtained at biopsy correlated with pulmonary hemodynamic findings after repair of congenital heart defects. Circulation. 1984;69(4):655–667. doi: 10.1161/01.cir.69.4.655. [DOI] [PubMed] [Google Scholar]
  • 216.Haworth SG, Reid L. Quantitative structural study of pulmonary circulation in the newborn with aortic atresia, stenosis, or coarctation. Thorax. 1977;32(2):121–128. doi: 10.1136/thx.32.2.121. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 217.Heath D, Edwards JE. The pathology of hypertensive pulmonary vascular disease; a description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects. Circulation. 1958;18(4 Part 1):533–547. doi: 10.1161/01.cir.18.4.533. [DOI] [PubMed] [Google Scholar]
  • 218.Clapp S, Perry BL, Farooki ZQ, Jackson WL, Karpawich PP, Hakimi M, et al. Down’s syndrome, complete atrioventricular canal, and pulmonary vascular obstructive disease. J Thorac Cardiovasc Surg. 1990;100(1):115–121. [PubMed] [Google Scholar]
  • 219.Hallidie-Smith KA, Hollman A, Cleland WP, Bentall HH, Goodwin JF. Effects of surgical closure of ventricular septal defects upon pulmonary vascular disease. Br Heart J. 1969;31(2):246–260. doi: 10.1136/hrt.31.2.246. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 220.Wessel DL, Adatia I, Giglia TM, Thompson JE, Kulik TJ. Use of inhaled nitric oxide and acetylcholine in the evaluation of pulmonary hypertension and endothelial function after cardiopulmonary bypass. Circulation. 1993;88(5 Pt 1):2128–2138. doi: 10.1161/01.cir.88.5.2128. [DOI] [PubMed] [Google Scholar]
  • 221.Atz AM, Adatia I, Lock JE, Wessel DL. Combined effects of nitric oxide and oxygen during acute pulmonary vasodilator testing. J Am Coll Cardiol. 1999;33(3):813–819. doi: 10.1016/s0735-1097(98)00668-8. [DOI] [PubMed] [Google Scholar]
  • 222.Balzer DT, Kort HW, Day RW, Corneli HM, Kovalchin JP, Cannon BC, et al. Inhaled Nitric Oxide as a Preoperative Test (INOP Test I): the INOP Test Study Group. Circulation. 2002;106(12 Suppl 1):I76–I81. [PubMed] [Google Scholar]
  • 223.Beghetti M, Adatia I. Inhaled nitric oxide and congenital cardiac disease. Cardiol Young. 2001;11(2):142–152. doi: 10.1017/s1047951101000038. [DOI] [PubMed] [Google Scholar]
  • 224.Yoshimura N, Yamaguchi M, Oka S, Yoshida M, Murakami H, Kagawa T, et al. Inhaled nitric oxide therapy after Fontan-type operations. Surg Today. 2005;35(1):31–35. doi: 10.1007/s00595-004-2887-1. [DOI] [PubMed] [Google Scholar]
  • 225.Kawakami H, Ichinose F. Inhaled nitric oxide in pediatric cardiac surgery. Int Anesthesiol Clin. 2004;42(4):93–100. doi: 10.1097/00004311-200404240-00010. [DOI] [PubMed] [Google Scholar]
  • 226.Miller OI, Tang SF, Keech A, Pigott NB, Beller E, Celermajer DS. Inhaled nitric oxide and prevention of pulmonary hypertension after congenital heart surgery: a randomised double-blind study. Lancet. 2000;356(9240):1464–1469. doi: 10.1016/S0140-6736(00)02869-5. [DOI] [PubMed] [Google Scholar]
  • 227.Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004;43(12 Suppl S):5S–12S. doi: 10.1016/j.jacc.2004.02.037. [DOI] [PubMed] [Google Scholar]
  • 228.D’Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991;115(5):343–349. doi: 10.7326/0003-4819-115-5-343. [DOI] [PubMed] [Google Scholar]
  • 229.Yamaki S, Wagenvoort CA. Comparison of primary plexogenic arteriopathy in adults and children. A morphometric study in 40 patients. Br Heart J. 1985;54(4):428–434. doi: 10.1136/hrt.54.4.428. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 230.Sandoval J, Bauerle O, Gomez A, Palomar A, Martinez Guerra ML, Furuya ME. Primary pulmonary hypertension in children: clinical characterization and survival. J Am Coll Cardiol. 1995;25(2):466–474. doi: 10.1016/0735-1097(94)00391-3. [DOI] [PubMed] [Google Scholar]
  • 231.Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med. 1987;107(2):216–223. doi: 10.7326/0003-4819-107-2-216. [DOI] [PubMed] [Google Scholar]
  • 232.Barst RJ, Stalcup SA, Steeg CN, Hall JC, Frosolono MF, Cato AE, et al. Relation of arachidonate metabolites to abnormal control of the pulmonary circulation in a child. Am Rev Respir Dis. 1985;131(1):171–177. doi: 10.1164/arrd.1985.131.1.171. [DOI] [PubMed] [Google Scholar]
  • 233.Newman CW, Jacobson GP, Hug GA, Weinstein BE, Malinoff RL. Practical method for quantifying hearing aid benefit in older adults. J Am Acad Audiol. 1991;2(2):70–75. [PubMed] [Google Scholar]
  • 234.Stewart DJ, Levy RD, Cernacek P, Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med. 1991;114(6):464–469. doi: 10.7326/0003-4819-114-6-464. [DOI] [PubMed] [Google Scholar]
  • 235.Giaid A. Nitric oxide and endothelin-1 in pulmonary hypertension. Chest. 1998;114(3 Suppl):208S–212S. doi: 10.1378/chest.114.3_supplement.208s. [DOI] [PubMed] [Google Scholar]
  • 236.Yuan JX, Aldinger AM, Juhaszova M, Wang J, Conte JV, Jr, Gaine SP. Dysfunctional voltage-gated K+ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation. 1998;98(14):1400–1406. doi: 10.1161/01.cir.98.14.1400. [DOI] [PubMed] [Google Scholar]
  • 237.Rabinovitch M, Andrew M, Thom H, Trusler GA, Williams WG, Rowe RD, et al. Abnormal endothelial factor VIII associated with pulmonary hypertension and congenital heart defects. Circulation. 1987;76(5):1043–1052. doi: 10.1161/01.cir.76.5.1043. [DOI] [PubMed] [Google Scholar]
  • 238.Geggel RL, Carvalho AC, Hoyer LW, Reid LM. von Willebrand factor abnormalities in primary pulmonary hypertension. Am Rev Respir Dis. 1987;135(2):294–299. doi: 10.1164/arrd.1987.135.2.294. [DOI] [PubMed] [Google Scholar]
  • 239.Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation. 1984;70(4):580–587. doi: 10.1161/01.cir.70.4.580. [DOI] [PubMed] [Google Scholar]
  • 240.Frank H, Mlczoch J, Huber K, Schuster E, Gurtner HP, Kneussl M. The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. Chest. 1997;112(3):714–721. doi: 10.1378/chest.112.3.714. [DOI] [PubMed] [Google Scholar]
  • 241.Thompson BT, Spence CR, Janssens SP, Joseph PM, Hales CA. Inhibition of hypoxic pulmonary hypertension by heparins of differing in vitro antiproliferative potency. Am J Respir Crit Care Med. 1994;149(6):1512–1517. doi: 10.1164/ajrccm.149.6.8004307. [DOI] [PubMed] [Google Scholar]
  • 242.Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992;327(2):76–81. doi: 10.1056/NEJM199207093270203. [DOI] [PubMed] [Google Scholar]
  • 243.Saji T, Ozawa Y, Ishikita T, Matsuura H, Matsuo N. Short-term hemodynamic effect of a new oral PGI2 analogue, beraprost, in primary and secondary pulmonary hypertension. Am J Cardiol. 1996;78(2):244–247. doi: 10.1016/s0002-9149(96)90408-7. [DOI] [PubMed] [Google Scholar]
  • 244.Nagaya N, Uematsu M, Okano Y, Satoh T, Kyotani S, Sakamaki F, et al. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. J Am Coll Cardiol. 1999;34(4):1188–1192. doi: 10.1016/s0735-1097(99)00312-5. [DOI] [PubMed] [Google Scholar]
  • 245.Hoeper MM, Schwarze M, Ehlerding S, Adler-Schuermeyer A, Spiekerkoetter E, Niedermeyer J, et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med. 2000;342(25):1866–1870. doi: 10.1056/NEJM200006223422503. [DOI] [PubMed] [Google Scholar]
  • 246.Higenbottam TW, Butt AY, Dinh-Xaun AT, Takao M, Cremona G, Akamine S. Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost. Heart. 1998;79(2):175–179. doi: 10.1136/hrt.79.2.175. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 247.Rich S, Seidlitz M, Dodin E, Osimani D, Judd D, Genthner D, et al. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest. 1998;114(3):787–792. doi: 10.1378/chest.114.3.787. [DOI] [PubMed] [Google Scholar]
  • 248.Cowan KN, Jones PL, Rabinovitch M. Elastase and matrix metallo-proteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease. J Clin Invest. 2000;105(1):21–34. doi: 10.1172/JCI6539. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 249.Cowan KN, Heilbut A, Humpl T, Lam C, Ito S, Rabinovitch M. Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor. Nat Med. 2000;6(6):698–702. doi: 10.1038/76282. [DOI] [PubMed] [Google Scholar]
  • 250.Barst RJ. Role of atrial septostomy in the treatment of pulmonary vascular disease. Thorax. 2000;55(2):95–96. doi: 10.1136/thorax.55.2.95. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 251.Mallory GB, Spray TL. Paediatric lung transplantation. Eur Respir J. 2004;24(5):839–845. doi: 10.1183/09031936.04.00064804. [DOI] [PubMed] [Google Scholar]
  • 252.Mendeloff EN, Meyers BF, Sundt TM, Guthrie TJ, Sweet SC de la Morena M, et al. Lung transplantation for pulmonary vascular disease. Ann Thorac Surg. 2002;73(1):209–219. doi: 10.1016/s0003-4975(01)03082-x. [DOI] [PubMed] [Google Scholar]
  • 253.Boucek MM, Edwards LB, Keck BM, Trulock EP, Taylor DO, Hertz MI. Registry for the International Society for Heart and Lung Transplantation: seventh official pediatric report—2004. J Heart Lung Transplant. 2004;23(8):933–947. doi: 10.1016/j.healun.2004.06.011. [DOI] [PubMed] [Google Scholar]
  • 254.Grover RF, Vogel JH, Voigt GC, Blount SG., Jr Reversal of high altitude pulmonary hypertension. Am J Cardiol. 1966;18(6):928–932. doi: 10.1016/0002-9149(66)90443-7. [DOI] [PubMed] [Google Scholar]
  • 255.Tucker A, McMurtry IF, Reeves JT, Alexander AF, Will DH, Grover RF. Lung vascular smooth muscle as a determinant of pulmonary hypertension at high altitude. Am J Physiol. 1975;228(3):762–767. doi: 10.1152/ajplegacy.1975.228.3.762. [DOI] [PubMed] [Google Scholar]
  • 256.Meyrick B, Reid L. Endothelial and subintimal changes in rat hilar pulmonary artery during recovery from hypoxia. A quantitative ultrastructural study. Lab Invest. 1980;42(6):603–615. [PubMed] [Google Scholar]
  • 257.Hultgren HN, Grover RF, Hartley LH. Abnormal circulatory responses to high altitude in subjects with a previous history of high-altitude pulmonary edema. Circulation. 1971;44(5):759–770. doi: 10.1161/01.cir.44.5.759. [DOI] [PubMed] [Google Scholar]
  • 258.Hanaoka M, Kubo K, Yamazaki Y, Miyahara T, Matsuzawa Y, Kobayashi T, et al. Association of high-altitude pulmonary edema with the major histocompatibility complex. Circulation. 1998;97(12):1124–1128. doi: 10.1161/01.cir.97.12.1124. [DOI] [PubMed] [Google Scholar]
  • 259.Cornfield DN, Reeve HL, Tolarova S, Weir EK, Archer S. Oxygen causes fetal pulmonary vasodilation through activation of a calcium-dependent potassium channel. Proc Natl Acad Sci USA. 1996;93(15):8089–8094. doi: 10.1073/pnas.93.15.8089. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 260.Wang Y, Coceani F. Isolated pulmonary resistance vessels from fetal lambs. Contractile behavior and responses to indomethacin and endothelin-1. Circ Res. 1992;71(2):320–330. doi: 10.1161/01.res.71.2.320. [DOI] [PubMed] [Google Scholar]
  • 261.Ivy DD, Parker TA, Kinsella JP, Abman SH. Endothelin A receptor blockade decreases pulmonary vascular resistance in premature lambs with hyaline membrane disease. Pediatr Res. 1998;44(2):175–180. doi: 10.1203/00006450-199808000-00006. [DOI] [PubMed] [Google Scholar]
  • 262.Chang JK, Moore P, Fineman JR, Soifer SJ, Heymann MA. K+ channel pulmonary vasodilation in fetal lambs: role of endothelium-derived nitric oxide. J Appl Physiol. 1992;73(1):188–194. doi: 10.1152/jappl.1992.73.1.188. [DOI] [PubMed] [Google Scholar]
  • 263.Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med. 2000;342(18):1334–1349. doi: 10.1056/NEJM200005043421806. [DOI] [PubMed] [Google Scholar]
  • 264.Zapol WM, Snider MT. Pulmonary hypertension in severe acute respiratory failure. N Engl J Med. 1977;296(9):476–480. doi: 10.1056/NEJM197703032960903. [DOI] [PubMed] [Google Scholar]
  • 265.Tomashefski JF, Jr, Davies P, Boggis C, Greene R, Zapol WM, Reid LM. The pulmonary vascular lesions of the adult respiratory distress syndrome. Am J Pathol. 1983;112(1):112–126. [PMC free article] [PubMed] [Google Scholar]
  • 266.Erdmann AJ, 3rd, Vaughan TR, Jr, Brigham KL, Woolverton WC, Staub NC. Effect of increased vascular pressure on lung fluid balance in unanesthetized sheep. Circ Res. 1975;37(3):271–284. doi: 10.1161/01.res.37.3.271. [DOI] [PubMed] [Google Scholar]
  • 267.Sibbald WJ, Driedger AA, Myers ML, Short AI, Wells GA. Biventricular function in the adult respiratory distress syndrome. Chest. 1983;84(2):126–134. doi: 10.1378/chest.84.2.126. [DOI] [PubMed] [Google Scholar]
  • 268.Katz R, Pollack M, Spady D. Cardiopulmonary abnormalities in severe acute respiratory failure. J Pediatr. 1984;104(3):357–364. doi: 10.1016/s0022-3476(84)81095-1. [DOI] [PubMed] [Google Scholar]
  • 269.Rossaint R, Falke KJ, Lopez F, Slama K, Pison U, Zapol WM. Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med. 1993;328(6):399–405. doi: 10.1056/NEJM199302113280605. [DOI] [PubMed] [Google Scholar]
  • 270.Fioretto JR de Moraes MA, Bonatto RC, Ricchetti SM, Carpi MF. Acute and sustained effects of early administration of inhaled nitric oxide to children with acute respiratory distress syndrome. Pediatr Crit Care Med. 2004;5(5):469–474. doi: 10.1097/01.pcc.0000137986.83738.d7. [DOI] [PubMed] [Google Scholar]
  • 271.Taylor RW, Zimmerman JL, Dellinger RP, Straube RC, Criner GJ, Davis K, Jr, et al. Low-dose inhaled nitric oxide in patients with acute lung injury: a randomized controlled trial. JAMA. 2004;291(13):1603–1609. doi: 10.1001/jama.291.13.1603. [DOI] [PubMed] [Google Scholar]
  • 272.Lundin S, Mang H, Smithies M, Stenqvist O, Frostell C. Inhalation of nitric oxide in acute lung injury: results of a European multicentre study. The European Study Group of Inhaled Nitric Oxide. Intensive Care Med. 1999;25(9):911–919. doi: 10.1007/s001340050982. [DOI] [PubMed] [Google Scholar]

Articles from The Respiratory Tract in Pediatric Critical Illness and Injury are provided here courtesy of Nature Publishing Group

RESOURCES